findmyKOL
Clinical trialNCT02713022CompletedObservational

Body Composition and White Adipose Tissue Inflammation

SponsorMemorial Sloan Kettering Cancer CenterEnrollment202Body CompositionBreast CancerProstate CancerWhite Adipose Tissue Inflammation
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators want to find a better way to predict the risk of having fatty tissue inflammation by using a different approach to finding out body fat composition. In this study, the investigators want to estimate the body fat composition using a DEXA scan. DEXA stands for dual energy X-ray absorptiometry. It is the standard and established test to determine bone mineral density (how strong the bones are) to diagnose osteoporosis. This test can also be used to determine the body composition including percent body fat and lean mass. The investigators will compare the participants DEXA scan results for body fat composition to the inflammation found in the breast tissue from the mastectomy to see if there is a relationship. If successful, this may help us predict which patients may be at risk for breast cancer in the future. In addition, the investigators will compare the participants DEXA scan results for body fat composition and inflammation found in the fat tissue from the mastectomy or prostatectomy to the level of exercise activity as measured by a short questionnaire to see if there is a relationship. The investigators will also measure the participants waist to hip ratio. Finally, at the time the participant has blood drawn for their standard presurgical testing, the investigators will also test the blood for prediabetes using a blood test called hemoglocin A1c. The investigators will also measure for the participants waist to hip ratio, and a Hgb A1c blood drawn will be take at the time of presurgical testing. If not feasible, Hgb A1c can be drawn at a separate visit prior to the DEXA scan. If successful, this may help us predict which patients may be at risk for breast cancer in the future.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Waters Corporation (data Analysis Only)

    Milford, Massachusetts, United States

  • Memorial Sloan Kettering Cancer Center (consent Only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (consent Only)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (consent Only)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center @ Commack (consent Only)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (consent Only)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Weill Medical College of Cornell University (data and Specimen Analysis Only)

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (consent Only)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Nov 2015
Primary completion
7 Nov 2023
Completion
7 Nov 2023
Last update posted
8 Nov 2023
Registered enrollment
202
Registry id
NCT02713022

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.